|
|
机会性筛查在心力衰竭预防中的意义及探讨
|
Abstract:
心力衰竭(heart failure, HF)是全球范围亟待解决的公众卫生问题。随着人口老龄化加剧和生活方式的改变，HF的发病率逐渐上升，给人们的健康带来了严重的威胁。HF机会性筛查是医生推荐给主动进行筛查的非HF就诊患者或体检人员进行的筛查，是一种低成本的筛查方式，在有效地提高人群对HF的认知度和对HF预防有着重大意义。目前在医防融合、资源共享的理念下，各级医疗机构和公共卫生机构能够协同合作从而更好推动HF筛查与预防。本文将结合最新指南对HF机会性筛查在预防中的重要价值作一综述，旨在为全科医生筛查和预防HF提供理论支持，提高全科医生早期干预管理HF的能力，降低医疗成本，履行时代赋予全科医生双“守门人”的职责，全面提升人民群众的健康水平和生活质量。
Heart failure (HF) is a public health issue that urgently needs to be addressed worldwide. With the increasing aging of the population and changes in lifestyle, the incidence of HF is gradually rising, posing a serious threat to people’s health. Opportunistic screening for HF is a type of screening recommended by doctors for patients who visit for reasons other than HF or for individuals undergoing physical examinations and who voluntarily undergo screening. It is a low-cost screening method that plays a significant role in effectively increasing public awareness of HF and in the prevention of HF. Under the current concept of integration of medical care and prevention and resource sharing, medical institutions at all levels and public health institutions can collaborate to better promote HF screening and prevention. This article will review the important value of opportunistic screening for HF in prevention in combination with the latest guidelines. It aims to provide theoretical support for general practitioners to screen and prevent HF, enhance their ability to intervene and manage HF at an early stage, reduce medical costs, fulfill the dual “gatekeeper” responsibilities assigned to general practitioners in this era, and comprehensively improve the health level and quality of life of the people.
| [1] | 国家心血管病中心, 国家心血管病专家委员会心力衰竭专业委员会, 中国医师协会心力衰竭专业委员会. 等. 国家心力衰竭指南2023 [J]. 中华心力衰竭和心肌病杂志, 2023, 7(4): 215-311. |
| [2] | Ambrosy, A.P., Fonarow, G.C., Butler, J., Chioncel, O., Greene, S.J., Vaduganathan, M., et al. (2014) The Global Health and Economic Burden of Hospitalizations for Heart Failure. Journal of the American College of Cardiology, 63, 1123-1133. https://doi.org/10.1016/j.jacc.2013.11.053 |
| [3] | 中国心衰中心工作报告(2021)——心力衰竭患者的诊疗现况[J]. 中国介入心脏病学杂志, 2022, 30(5): 328-336. |
| [4] | 中国老年医学会心电与心功能分会, 中国心衰中心联盟专家委员会, 中华医学会《中华全科医师杂志》编辑委员会. 心力衰竭早期筛查与一级预防中国专家共识(2024年) [J]. 中华全科医师杂志, 2024, 23(1): 7-18. |
| [5] | 郭艺芳. 2022年美国心力衰竭管理指南更新要点解读[J]. 中国全科医学, 2022, 25(17): 2051-2054. |
| [6] | 张健, 张宇辉, 周蕾. 国家心力衰竭指南2023 (精简版) [J]. 中国循环杂志, 2023, 38(12): 1207-1238. |
| [7] | Lund, L.H., Hage, C. and Savarese, G. (2021) Implementation Science and Potential for Screening in Heart Failure. European Heart Journal, 43, 413-415. https://doi.org/10.1093/eurheartj/ehab751 |
| [8] | Kahn, M., Grayson, A.D., Chaggar, P.S., Ng Kam Chuen, M.J., Scott, A., Hughes, C., et al. (2021) Primary Care Heart Failure Service Identifies a Missed Cohort of Heart Failure Patients with Reduced Ejection Fraction. European Heart Journal, 43, 405-412. https://doi.org/10.1093/eurheartj/ehab629 |
| [9] | 王雨妃, 王传合, 孙志军. 中性粒细胞/淋巴细胞比值对射血分数保留的心力衰竭患者远期预后的影响[J]. 中国循环杂志, 2023, 38(5): 554-559. |
| [10] | 许名东, 李丽华, 李晚泉, 等. 慢性心力衰竭患者血浆半乳糖凝集素-3与动脉僵硬度的相关性[J]. 广东医科大学学报, 2022, 40(2): 169-172. |
| [11] | (2022) Correction to: 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 145, e1033. |
| [12] | Moura, B., Aimo, A., Al‐Mohammad, A., Flammer, A., Barberis, V., Bayes‐Genis, A., et al. (2021) Integration of Imaging and Circulating Biomarkers in Heart Failure: A Consensus Document by the Biomarkers and Imaging Study Groups of the Heart Failure Association of the European Society of Cardiology. European Journal of Heart Failure, 23, 1577-1596. https://doi.org/10.1002/ejhf.2339 |
| [13] | 李莹莹, 朱婉榕, 柴坷, 等. 85岁及以上射血分数保留的心力衰竭患者心肌淀粉样物质沉积分析[J]. 中华心血管病杂志, 2018, 46(6): 438-443. |
| [14] | Kampman, M.A.M., Balci, A., van Veldhuisen, D.J., van Dijk, A.P.J., Roos-Hesselink, J.W., Sollie-Szarynska, K.M., et al. (2013) N-Terminal Pro-B-Type Natriuretic Peptide Predicts Cardiovascular Complications in Pregnant Women with Congenital Heart Disease. European Heart Journal, 35, 708-715. https://doi.org/10.1093/eurheartj/eht526 |
| [15] | Pandey, A., Garg, S., Khunger, M., Darden, D., Ayers, C., Kumbhani, D.J., et al. (2015) Dose-Response Relationship between Physical Activity and Risk of Heart Failure: A Meta-Analysis. Circulation, 132, 1786-1794. https://doi.org/10.1161/circulationaha.115.015853 |
| [16] | He, J., Ogden, L.G., Bazzano, L.A., Vupputuri, S., Loria, C. and Whelton, P.K. (2001) Risk Factors for Congestive Heart Failure in US Men and Women: NHANES I Epidemiologic Follow-Up Study. Archives of Internal Medicine, 161, 996-1002. https://doi.org/10.1001/archinte.161.7.996 |
| [17] | Chen, X., Thunström, E., Hansson, P., Rosengren, A., Mandalenakis, Z., Zhong, Y., et al. (2019) High Prevalence of Cardiac Dysfunction or Overt Heart Failure in 71-Year-Old Men: A 21-Year Follow-Up of “the Study of Men Born in 1943”. European Journal of Preventive Cardiology, 27, 717-725. https://doi.org/10.1177/2047487319871644 |
| [18] | Wang, Y., Tuomilehto, J., Jousilahti, P., Antikainen, R., Mähönen, M., Katzmarzyk, P.T., et al. (2011) Lifestyle Factors in Relation to Heart Failure among Finnish Men and Women. Circulation: Heart Failure, 4, 607-612. https://doi.org/10.1161/circheartfailure.111.962589 |
| [19] | Pandey, A., Allen, N.B., Ayers, C., Reis, J.P., Moreira, H.T., Sidney, S., et al. (2017) Fitness in Young Adulthood and Long-Term Cardiac Structure and Function: The CARDIA Study. JACC: Heart Failure, 5, 347-355. https://doi.org/10.1016/j.jchf.2016.11.014 |
| [20] | Kamimura, D., Loprinzi, P.D., Wang, W., Suzuki, T., Butler, K.R., Mosley, T.H., et al. (2017) Physical Activity Is Associated with Reduced Left Ventricular Mass in Obese and Hypertensive African Americans. American Journal of Hypertension, 30, 617-623. https://doi.org/10.1093/ajh/hpx044 |
| [21] | 杨若彤, 韩雨廷, 吕筠, 等. 中国10个地区成年人心力衰竭流行情况及其吸烟影响因素研究[J]. 中华流行病学杂志, 2021, 42(5): 787-793. |
| [22] | Lu, Y., Xu, Z., Georgakis, M.K., Wang, Z., Lin, H. and Zheng, L. (2021) Smoking and Heart Failure: A Mendelian Randomization and Mediation Analysis. ESC Heart Failure, 8, 1954-1965. https://doi.org/10.1002/ehf2.13248 |
| [23] | Lin, G., Lloyd‐Jones, D.M., Colangelo, L.A., Lima, J.A.C., Szklo, M. and Liu, K. (2024) Association between Secondhand Smoke Exposure and Incident Heart Failure: The Multi-Ethnic Study of Atherosclerosis (Mesa). European Journal of Heart Failure, 26, 199-207. https://doi.org/10.1002/ejhf.3155 |
| [24] | Moreira, H.T., Armstrong, A.C., Nwabuo, C.C., Vasconcellos, H.D., Schmidt, A., Sharma, R.K., et al. (2020) Association of Smoking and Right Ventricular Function in Middle Age: CARDIA Study. Open Heart, 7, e001270. https://doi.org/10.1136/openhrt-2020-001270 |
| [25] | Hendriks, T., van Dijk, R., Alsabaan, N.A. and van der Harst, P. (2020) Active Tobacco Smoking Impairs Cardiac Systolic Function. Scientific Reports, 10, Article No. 6608. https://doi.org/10.1038/s41598-020-63509-3 |
| [26] | Son, Y. and Lee, H. (2020) Association between Persistent Smoking after a Diagnosis of Heart Failure and Adverse Health Outcomes: A Systematic Review and Meta-Analysis. Tobacco Induced Diseases, 18, Article 5. https://doi.org/10.18332/tid/116411 |
| [27] | Wang, S. and Ren, J. (2018) Role of Autophagy and Regulatory Mechanisms in Alcoholic Cardiomyopathy. Biochimica et Biophysica Acta (BBA)—Molecular Basis of Disease, 1864, 2003-2009. https://doi.org/10.1016/j.bbadis.2018.03.016 |
| [28] | Bozkurt, B., Hershberger, R.E., Butler, J., Grady, K.L., Heidenreich, P.A., Isler, M.L., et al. (2021) 2021 ACC/AHA Key Data Elements and Definitions for Heart Failure. Journal of the American College of Cardiology, 77, 2053-2150. https://doi.org/10.1016/j.jacc.2020.11.012 |
| [29] | Rodrigues, P., Santos-Ribeiro, S., Teodoro, T., Gomes, F.V., Leal, I., Reis, J.P., et al. (2018) Association between Alcohol Intake and Cardiac Remodeling. Journal of the American College of Cardiology, 72, 1452-1462. https://doi.org/10.1016/j.jacc.2018.07.050 |
| [30] | Guillo, P., Mansourati, J., Maheu, B., Etienne, Y., Provost, K., Simon, O., et al. (1997) Long-Term Prognosis in Patients with Alcoholic Cardiomyopathy and Severe Heart Failure after Total Abstinence. The American Journal of Cardiology, 79, 1276-1278. https://doi.org/10.1016/s0002-9149(97)00101-x |
| [31] | Nicolás, J.M., Fernández-Solà, J., Estruch, R., Paré, J.C., Sacanella, E., Urbano-Márquez, A., et al. (2002) The Effect of Controlled Drinking in Alcoholic Cardiomyopathy. Annals of Internal Medicine, 136, 192-200. https://doi.org/10.7326/0003-4819-136-3-200202050-00007 |
| [32] | Delgado-Lista, J., Alcala-Diaz, J.F., Torres-Pea, J.D., et al. (2022) Long-Term Secondary Prevention of Cardiovascular Disease with a Mediterranean Diet and a Low-Fat Diet (CORDIOPREV): A Randomised Controlled Trial. Lancet, 399, 1876-1885. |
| [33] | Iqbal, J., Wu, H., Hu, N., Zhou, Y., Li, L., Xiao, F., et al. (2022) Effect of Glucagon‐Like Peptide‐1 Receptor Agonists on Body Weight in Adults with Obesity without Diabetes Mellitus—A Systematic Review and Meta‐Analysis of Randomized Control Trials. Obesity Reviews, 23, e13435. https://doi.org/10.1111/obr.13435 |
| [34] | Vasan, R.S. (1996) The Role of Hypertension in the Pathogenesis of Heart Failure. Archives of Internal Medicine, 156, 1789-1796. https://doi.org/10.1001/archinte.1996.00440150033003 |
| [35] | de Simone, G., Gottdiener, J.S., Chinali, M. and Maurer, M.S. (2008) Left Ventricular Mass Predicts Heart Failure Not Related to Previous Myocardial Infarction: The Cardiovascular Health Study. European Heart Journal, 29, 741-747. https://doi.org/10.1093/eurheartj/ehm605 |
| [36] | Upadhya, B., Rocco, M., Lewis, C.E., Oparil, S., Lovato, L.C., Cushman, W.C., et al. (2017) Effect of Intensive Blood Pressure Treatment on Heart Failure Events in the Systolic Blood Pressure Reduction Intervention Trial. Circulation: Heart Failure, 10, e003613. https://doi.org/10.1161/circheartfailure.116.003613 |
| [37] | Verdecchia, P., Angeli, F., Cavallini, C., Gattobigio, R., Gentile, G., Staessen, J.A., et al. (2008) Blood Pressure Reduction and Renin-Angiotensin System Inhibition for Prevention of Congestive Heart Failure: A Meta-Analysis. European Heart Journal, 30, 679-688. https://doi.org/10.1093/eurheartj/ehn575 |
| [38] | Ettehad, D., Emdin, C.A., Kiran, A., Anderson, S.G., Callender, T., Emberson, J., et al. (2016) Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-analysis. The Lancet, 387, 957-967. https://doi.org/10.1016/s0140-6736(15)01225-8 |
| [39] | Komajda, M., McMurray, J.J.V., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Pocock, S.J., et al. (2010) Heart Failure Events with Rosiglitazone in Type 2 Diabetes: Data from the RECORD Clinical Trial. European Heart Journal, 31, 824-831. https://doi.org/10.1093/eurheartj/ehp604 |
| [40] | Li, Y., Wang, B., Fan, F., Zhang, Y., Jiang, J., LI, J., et al. (2023) Thirty-day Outcomes of In-Hospital Multi-Vessel versus Culprit-Only Revascularization Strategy for ST-Segment Elevation Myocardial Infarction with Multivessel Coronary Disease. Journal of Geriatric Cardiology, 20, 485-494. https://doi.org/10.26599/1671-5411.2023.07.005 |
| [41] | Mehta, S.R., Wood, D.A., Storey, R.F., Mehran, R., Bainey, K.R., Nguyen, H., et al. (2019) Complete Revascularization with Multivessel PCI for Myocardial Infarction. New England Journal of Medicine, 381, 1411-1421. https://doi.org/10.1056/nejmoa1907775 |
| [42] | Wu, H., Xu, L., Zhao, X., Zhang, H., Cheng, K., Wang, X., et al. (2023) Indobufen or Aspirin on Top of Clopidogrel after Coronary Drug-Eluting Stent Implantation (OPTION): A Randomized, Open-Label, End Point-Blinded, Noninferiority Trial. Circulation, 147, 212-222. https://doi.org/10.1161/circulationaha.122.062762 |
| [43] | Latib, A., Ielasi, A., Ferri, L., Chieffo, A., Godino, C., Carlino, M., et al. (2013) Aspirin Intolerance and the Need for Dual Antiplatelet Therapy after Stent Implantation: A Proposed Alternative Regimen. International Journal of Cardiology, 165, 444-447. https://doi.org/10.1016/j.ijcard.2011.08.080 |
| [44] | Nakamura, K., Miyoshi, T., Yoshida, M., Akagi, S., Saito, Y., Ejiri, K., et al. (2022) Pathophysiology and Treatment of Diabetic Cardiomyopathy and Heart Failure in Patients with Diabetes Mellitus. International Journal of Molecular Sciences, 23, Article 3587. https://doi.org/10.3390/ijms23073587 |
| [45] | Kannel, W.B. (1979) Diabetes and Cardiovascular Disease: The Framingham Study. JAMA, 241, 2035-2038. https://doi.org/10.1001/jama.1979.03290450033020 |
| [46] | Zinman, B.L., John, M., et al. (2016) Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes REPLY. The New England Journal of Medicine, 374, 1094-1094. |
| [47] | Rosenstock, J., Perkovic, V., Johansen, O.E., Cooper, M.E., Kahn, S.E., Marx, N., et al. (2019) Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults with Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA, 321, 69-79. https://doi.org/10.1001/jama.2018.18269 |
| [48] | Scirica, B.M., Bhatt, D.L., Braunwald, E., Steg, P.G., Davidson, J., Hirshberg, B., et al. (2013) Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. New England Journal of Medicine, 369, 1317-1326. https://doi.org/10.1056/nejmoa1307684 |
| [49] | Waijer, S.W., Vart, P., Cherney, D.Z.I., Chertow, G.M., Jongs, N., Langkilde, A.M., et al. (2022) Effect of Dapagliflozin on Kidney and Cardiovascular Outcomes by Baseline KDIGO Risk Categories: A Post Hoc Analysis of the DAPA-CKD Trial. Diabetologia, 65, 1085-1097. https://doi.org/10.1007/s00125-022-05694-6 |
| [50] | Fernández-Fernandez, B., Sarafidis, P., Soler, M.J. and Ortiz, A. (2023) EMPA-KIDNEY: Expanding the Range of Kidney Protection by SGLT2 Inhibitors. Clinical Kidney Journal, 16, 1187-1198. https://doi.org/10.1093/ckj/sfad082 |
| [51] | Baigent, C., Emberson, J., Haynes, R., Herrington, W.G., Judge, P., Landray, M.J., et al. (2022) Impact of Diabetes on the Effects of Sodium Glucose Co-Transporter-2 Inhibitors on Kidney Outcomes: Collaborative Meta-Analysis of Large Placebo-Controlled Trials. The Lancet, 400, 1788-1801. https://doi.org/10.1016/s0140-6736(22)02074-8 |
| [52] | Filippatos, G., Anker, S.D., Agarwal, R., Ruilope, L.M., Rossing, P., Bakris, G.L., et al. (2022) Finerenone Reduces Risk of Incident Heart Failure in Patients with Chronic Kidney Disease and Type 2 Diabetes: Analyses from the FIGARO-DKD Trial. Circulation, 145, 437-447. https://doi.org/10.1161/circulationaha.121.057983 |
| [53] | Ruilope, L.M., Pitt, B., Anker, S.D., Rossing, P., Kovesdy, C.P., Pecoits-Filho, R., et al. (2022) Kidney Outcomes with Finerenone: An Analysis from the FIGARO-DKD Study. Nephrology Dialysis Transplantation, 38, 372-383. https://doi.org/10.1093/ndt/gfac157 |
| [54] | Agarwal, R., Filippatos, G., Pitt, B., Anker, S.D., Rossing, P., Joseph, A., et al. (2021) Cardiovascular and Kidney Outcomes with Finerenone in Patients with Type 2 Diabetes and Chronic Kidney Disease: The FIDELITY Pooled Analysis. European Heart Journal, 43, 474-484. https://doi.org/10.1093/eurheartj/ehab777 |
| [55] | Hantson, P. (2018) Mechanisms of Toxic Cardiomyopathy. Clinical Toxicology, 57, 1-9. https://doi.org/10.1080/15563650.2018.1497172 |
| [56] | Aleman, B.M.P., van den Belt-Dusebout, A.W., De Bruin, M.L., van’t Veer, M.B., Baaijens, M.H.A., Boer, J.P.d., et al. (2006) Late Cardiotoxicity after Treatment for Hodgkin Lymphoma. Blood, 109, 1878-1886. https://doi.org/10.1182/blood-2006-07-034405 |
| [57] | 花晓莉, 钱海芹, 季祥霞, 等. 多学科合作诊疗创新家庭医生服务模式实践探索[J]. 中国卫生标准管理, 2024, 15(4): 101-104. |
| [58] | 张影, 崔明, 韩君华, 等. 家庭医生签约服务模式对社区老年居民心血管疾病风险管理效果的影响[J]. 同济大学学报(医学版), 2023, 44(1): 97-104. |
| [59] | Lund, L.H., Trochu, J., Meyns, B., Caliskan, K., Shaw, S., Schmitto, J.D., et al. (2017) Screening for Heart Transplantation and Left Ventricular Assist System: Results from the Screening for Advanced Heart Failure Treatment (SEE‐HF) Study. European Journal of Heart Failure, 20, 152-160. https://doi.org/10.1002/ejhf.975 |
| [60] | Soundarraj, D., Singh, V., Satija, V. and Thakur, R.K. (2017) Containing the Cost of Heart Failure Management: A Focus on Reducing Read-Missions. Heart Failure Clinics, 13, 21-28. https://doi.org/10.1016/j.hfc.2016.07.002 |
